BiotechTube

MIJ821 + Placebo + Ketamine

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Depressive Disorder, Treatment-Resistant

Conditions

Depressive Disorder, Treatment-Resistant

Trial Timeline

Feb 8, 2019 → Mar 23, 2020

NCT ID
NCT03756129

About MIJ821 + Placebo + Ketamine

MIJ821 + Placebo + Ketamine is a phase 2 stage product being developed by Novartis for Depressive Disorder, Treatment-Resistant. The current trial status is completed. This product is registered under clinical trial identifier NCT03756129. Target conditions include Depressive Disorder, Treatment-Resistant.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03756129Phase 2Completed

Competing Products

20 competing products in Depressive Disorder, Treatment-Resistant

See all competitors
ProductCompanyStageHype Score
duloxetineEli LillyPre-clinical
23
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
Duloxetine HydrochlorideShionogiPhase 3
77
Duloxetine Hydrochloride + PlaceboShionogiPhase 3
77
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85